The Immunohistochemical Analysis of Antigens such as <scp>RCAS</scp>1 and <scp>B</scp>7<scp>H</scp>4 in the Cervical Cancer Nest and within the Fibroblasts and Macrophages Infiltrating the Cancer Microenvironment

Gałązka, Krystyna; Opławski, Marcin; Windorbska, Wiesława; Skręt-Magierło, Joanna; Koper, Krzysztof; Basta, Paweł; Mach, Paweł; Dutch-Wicherek, Magdalena; Mazur, Aleksandra; Wicherek, Lukasz

doi:10.1111/j.1600-0897.2012.01134.x

Cited by 15 publications

(12 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results were previously reported (20). In addition to tumor cells, tumor-infiltrating macrophages (8,15,21) and the endothelial cells of small blood vessels in the cancer microenvironment were also found to constitutively express B7-H4. B7-H4 was also found to be highly expressed on tumor-associated macrophages in the ascites of ovarian cancer patients and may contribute to tumor progression (15).…”

Section: Discussionsupporting

confidence: 89%

B7-H4 overexpression correlates with a poor prognosis for cervical cancer patients

Liu

Shibata

Koya³

et al. 2013

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Cervical cancer is a major global public health care concern and the second most commonly diagnosed malignancy among females worldwide. B7-H4 is an immunoregulatory protein that has been shown to be overexpressed in several types of cancer and is often associated with more advanced disease and poor prognosis. We investigated whether B7-H4 is a prognostic maker for cervical cancer by detecting its expression in cervical cancer specimens. Formalin-fixed, paraffin-embedded tissue blocks from cervical cancer were evaluated for B7-H4 expression by immunohistochemistry with free R software analysis. The intensity of B7-H4 immunoexpression was evaluated according to age, histological type, International Federation of Gynecology and Obstetrics (FIGO) stage, lymphovascular space invasion (LVSI) and lymph node status. We investigated the distribution and expression of B7-H4 in 102 cervical cancer specimens and determined the association between its expression and clinicopathological characteristics, including patient outcomes. Of the 102 specimens, 31 were found to be negative for B7-H4 immunoexpression, whereas 71 were B7-H4-positive. When classified by negative vs. positive expression, B7-H4 was not found to be associated with any of the clinicopathological parameters investigated. A positive B7-H4 expression significantly predicted poor overall survival (OS) when compared to negative expression (P<0.05). In the multivariate analysis, positive B7-H4 expression was identified as an independent prognostic factor for OS (P<0.05). Our data suggested that positive B7-H4 expression may be a useful biomarker in patients with cervical cancer likely to have an unfavorable clinical outcome.

show abstract

Section: Discussionsupporting

confidence: 89%

B7-H4 overexpression correlates with a poor prognosis for cervical cancer patients

Liu

Shibata

Koya³

et al. 2013

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…15 In one of our previous studies, we found that RCAS1 immunoreactivity levels on the front of the cervical cancer nest were positively correlated with both the FIGO stage and with the extent of the local spread, thus indicating a more aggressive phenotype. 31 In the present study, we found no differences in the serum sRCAS1 levels between early and advanced stage cervical cancer patients. This finding accords with the original report by Sonoda et al 7 However, in a different study by the Japanese group, the authors reported that not all RCAS1-expressing cells secreted sRCAS1 to the blood stream.…”

Section: Discussioncontrasting

confidence: 59%

“…In a further study by Sonoda et al ., RCAS1 over‐expression in cervical cancer samples was positively correlated with invasion of the lymph‐vascular space, multiple lymph node metastases and tumor volume . In one of our previous studies, we found that RCAS1 immunoreactivity levels on the front of the cervical cancer nest were positively correlated with both the FIGO stage and with the extent of the local spread, thus indicating a more aggressive phenotype . In the present study, we found no differences in the serum sRCAS1 levels between early and advanced stage cervical cancer patients.…”

Section: Discussionsupporting

confidence: 52%

High post‐treatment serum soluble receptor‐binding cancer antigen expressed on SiSo cells (sRCAS1) levels is associated with poor survival of patients with cervical cancer

Szubert

Dziobek

Wicherek

2020

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Aim Receptor‐binding cancer antigen expressed on SiSo cells (sRCAS1) is responsible for induction of selective immunosuppression. In addition, preclinical studies have shown that sRCAS1 levels may reflect cancer aggressiveness. The main aim of our study was to analyze pre‐ and post‐treatment levels of sRCAS1 in the sera of patients treated for cervical cancer and to evaluate whether the levels change during treatment and their impact on patient prognosis. Methods The study included 49 patients suffering from cervical cancer. The early stage cervical cancer patients (14) were treated surgically, while the advanced stage patients (35) underwent radiochemotherapy. Serum sRCAS1 levels were evaluated both before and after intervention with the use of the ELISA method. Results We have found that median serum sRCAS1 levels of patients before intervention were not significantly different from the levels assessed after intervention. There were also no differences when pre‐ and post‐treatment levels were compared within the group of early and of advanced stage patients. Serum sRCAS1 levels were not influenced by either the histopathological type of the tumor or the methods of treatment. High post‐intervention sRCAS1 levels indicated shortened OS when compared to low sRCAS1 levels. Neither pre‐intervention sRCAS1 levels nor the alteration in sRCAS1 levels during treatment were associated with patient prognosis. In multivariate analysis, post‐treatment sRCAS1 levels and clinical stage of cervical cancer remained as independent predictors of survival. Conclusion High post‐treatment serum sRCAS1 level in cervical cancer patients seems to be a negative prognostic factor for patient overall survival.

show abstract

“…Receptor-binding cancer antigen expressed on SiSo cells (RCAS1) was discovered in 1996 by Sonoda et al [8] as a membrane protein present on cervical cancer cells. RCAS1 expression was found on a variety of cells, including T, B, and NK cells, and on macrophages, fibroblasts, and human neoplastic cells [9]. RCAS1 acts through the putative receptor, and its main function is related to the induction of selective immunosuppression.…”

Section: Introductionmentioning

confidence: 99%

The potential predictive value of serum srCaS1 levels for overall survival in endometrial cancer

Szubert¹,

Koper

Dutsch-Wicherek

et al. 2019

Ginekol Pol

Self Cite

View full text Add to dashboard Cite

Objectives:The main aim of the study was to evaluate the impact of levels of serum soluble receptor-binding cancer antigen expressed on SiSo cells (sRCAS1) on the overall survival (OS) rates in patients with endometrial cancer. Furthermore, we analyzed sRCAS1 levels according to the clinicopathological characteristics of the disease. Material and methods:The study group comprised 43 patients who were being treated for endometrial cancer. We included 10 low-risk, 20 intermediate-risk and 13 high-risk endometrial cancers using the criteria of the European Society for Medical Oncology (ESMO), the European Society for Radiotherapy & Oncology (ESTRO) and the European Society of Gynaecological Oncology (ESGO). Serum sRCAS1 levels were obtained before and after surgery. Serum sRCAS1 levels were assessed using the ELISA method. Results:In our univariate analysis, both the pre-and post-surgery high sRCAS1 groups of patients with endometrial cancer indicated a shortened OS. However, in our multivariate analysis, when patients' age and disease-related risk was taken into consideration, only the post-surgery sRCAS1 levels remained as independent prognostic factors of a poor OS. Pre-treatment serum sRCAS1 levels were statistically significantly higher than post-surgery sRCAS1 levels; however, the difference between pre-and post-surgery sRCAS1 levels did not influence the patients' OS rate. Pre-and post-surgery sRCAS1 levels did not differ according to tumor grade, stage of the disease or the disease-related risk group. Conclusions:High post-surgery serum sRCAS1 levels seem to be an independent indicator of shortened overall survival in patients with endometrial cancer.

show abstract

The Immunohistochemical Analysis of Antigens such as RCAS1 and B7H4 in the Cervical Cancer Nest and within the Fibroblasts and Macrophages Infiltrating the Cancer Microenvironment

Cited by 15 publications

References 30 publications

B7-H4 overexpression correlates with a poor prognosis for cervical cancer patients

B7-H4 overexpression correlates with a poor prognosis for cervical cancer patients

High post‐treatment serum soluble receptor‐binding cancer antigen expressed on SiSo cells (sRCAS1) levels is associated with poor survival of patients with cervical cancer

The potential predictive value of serum srCaS1 levels for overall survival in endometrial cancer

Contact Info

Product

Resources

About